Company Details
Name: RoslinCT
Date Founded: 2006
Sector: Life Sciences
Key Products/Services: Advanced cell therapy CDMO offerings including Process & Analytical development, cGMP Cell Banking, cGMP iPSC Development, Manufacturing Science & Technology, Clinical & Commercial Manufacturing, Quality & Regulatory Compliance, and Supply Chain Logistics.
Website URL: www.roslinCT.com
Executive Summary
RoslinCT is a pioneering global CDMO, established in 2006 to translate cutting-edge science into real-world treatments by manufacturing advanced cell & gene therapies.
It was among the first in the world to produce clinical-grade human pluripotent stem cells and partnered with Vertex to develop the first CRISPR-edited cell therapy (exa-cel/CASGEVY) from development through commercial launch.
With facilities in Edinburgh and Boston featuring 22 purpose-built cGMP suites, RoslinCT offers comprehensive development-to-commercial manufacturing services, backed by deep scientific expertise and a strong quality and regulatory record.
Over the years, the company has grown significantly, expanding its workforce from a small founding team to more than 450 employees globally, with the majority based in Scotland – demonstrating its scale-up capability and contribution to the UK life sciences sector.
The Challenge
The central challenge RoslinCT set out to address was the lack of scalable, high-quality contract manufacturing infrastructure tailored for advanced cell and gene therapies. As the field evolved rapidly, academic and biotech developers needed partners capable of delivering cGMP-compliant iPSC lines, process development, regulatory-quality manufacturing, and post-manufacturing logistics across both the UK and U.S. markets. This gap threatened to slow the transition of life-saving therapies from discovery to patients.
The Solution
RoslinCT responded by building a global footprint of purpose-built, fully licensed cGMP manufacturing and development facilities in Edinburgh (UK) and Hopkinton, Massachusetts (U.S.), with a total of 22 processing suites. They developed end-to-end CDMO capabilities spanning iPSC creation, gene editing, process development, analytics, and commercialization-ready production—all under rigorous quality and regulatory frameworks.
Their integration with software systems for electronic batch records and supply chain oversight further enhanced operational agility and compliance.
The Impact
First CRISPR-edited cell therapy: RoslinCT played a pivotal role in developing Vertex’s exa-cel (CASGEVY), the first CRISPR-based cell therapy approved in Great Britain for sickle cell disease and transfusion-dependent beta thalassemia.
Strategic partnership for Omisirge® manufacturing: In March 2025, RoslinCT announced a major partnership with Ayrmid Pharma (Gamida Cell) to manufacture FDA-approved Omisirge®, expanding its commercial footprint in the U.S.
Growth and expansion: The company expanded its Process Development labs and offices at Edinburgh Technopole to meet growing market demand.
Global capacity and scale: Through integration with Lykan Bioscience in 2023, RoslinCT reinforced its global CDMO presence with enhanced resources and transatlantic manufacturing capabilities.
Headcount growth: From its origins as a small team, RoslinCT now employs over 450 people worldwide, with the majority based in Scotland, underlining its role as a driver of high-
Future Plans
RoslinCT is focused on expanding both its capacity and technology offerings.
Key initiatives include further scaling of its Edinburgh and Boston facilities to meet rising demand, diversifying capabilities to support viral gene-modified therapies, and deepening its commercial partnerships to bring more innovative therapies to market sustainably and efficiently.
As part of this growth, RoslinCT plans to continue expanding its headcount, creating high-value roles and developing a strong talent pool in Scotland and the wider UK to meet the increasing demand for skilled professionals in advanced therapies.
The company is also committed to enhancing sustainability practices, reducing its carbon footprint across operations, and strengthening its social impact through community engagement and STEM education initiatives.